{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"40.00","upperLimit":"1230.00","value":"483.00"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"description":"Serum levels were determined for 38 circulating proteins. Selected value showing statistically significant difference compared with baseline is reported here.","dispersionType":"Full Range","groups":[{"description":"Participants received oral doses of glasdegib tablets 100 mg QD in 28-day cycles on a continuous basis, starting on Day 1 of Cycle 1. LDAC was given at a dose of 20 mg subcutaneously BID on Days 1-10 of the 28 day cycles.","id":"OG000","title":"Phase 2 Unfit: Glasdegib 100 mg + LDAC"}],"paramType":"MEDIAN","populationDescription":"PD analysis set: all enrolled participants in the Phase 2 Unfit portion who received at least 1 dose of glasdegib, and had at least 1 PD parameter from the corresponding assay sample with a baseline and an adequate post treatment assessment.","reportingStatus":"POSTED","timeFrame":"Cycle 1/Day 1, 1 Hour Post dose","title":"Serum Levels of Circulating Protein Analytes at Phase 2 Unfit - Cycle 1/Day 1","type":"SECONDARY","unitOfMeasure":"pg/mL"}